Skip to main
PFE

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 21%
Buy 14%
Hold 57%
Sell 7%
Strong Sell 0%

Bulls say

Pfizer is positioned for strong growth with its portfolio of top-selling products, global reach with a strong presence in emerging markets, and a robust pipeline with potential catalysts in the near future such as the MEVPRO-1 data and Litfulo Phase 3 data. There are potential risks, such as disappointing clinical data or regulatory setbacks in the pipeline and macroeconomic concerns, but the potential upside outweighs these risks, making Pfizer a strong investment opportunity with an expected 6% upside and limited downside.

Bears say

Pfizer is facing numerous challenges, including increasing competition and significant patent expirations in the coming years. In addition, their recent cost-cutting program and R&D cuts in infectious diseases raise questions about their sustainability initiatives and global health leadership. The company's limited diversity at the C-suite level and concerns over their COVID-19 vaccine pricing strategy also impact their strategic credibility. These factors, combined with their lower growth profile and higher exposure to LOEs, justify our negative outlook on the stock and our underperform rating and price target.

Pfizer (PFE) has been analyzed by 14 analysts, with a consensus rating of Hold. 21% of analysts recommend a Strong Buy, 14% recommend Buy, 57% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Hold based on their latest research and market trends.

According to 14 analysts, Pfizer (PFE) has a Hold consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.